

**INFORMATION ABOUT THE FACTS AND CIRCUMSTANCES OCCURRED  
DURING THE FIRST THREE MONTHS OF 2026  
OF "SOPHARMA" GROUP**

**Annex № 4**

**To Art. 12, par. 1, it.1, art.14 of Ordinance № 2 from 09.11.2021  
And Regulation (EU) 596/2014 of the European Parliament and of the Council  
of 16 April 2014**

*The persons who are liable for damages caused by false, misleading or incomplete data in this information as of 31.03.2026 are:*

*Ognian Donev - Executive Director and Chairman of the Board of Directors of "Sopharma" AD  
Vesela Stoeva – Deputy. - Chairman of the Board of Directors of "Sopharma" AD  
Bissera Lazarova – Member of the Board of Directors of "Sopharma" AD  
Aleksandar Tchaoushev – Member of the Board of Directors of "Sopharma" AD  
Ivan Badinski - Member of the Board of Directors of "Sopharma" AD*

- 1.1. No change in the persons controlling the Company.
- 1.2. No opening of bankruptcy proceedings against the company or its subsidiary or any significant events related to production.
- 1.3. There are no significant transactions.
- 1.4. No decision on conclusion, termination and cancellation of joint venture agreements.
- 1.5. Change of the auditors of the company - No change of auditors.
- 1.6. There is no opening or termination of a court or arbitration case relating to the debts or claims of the company or its subsidiary with a claim price of at least 10% of the company's equity.
- 1.7. No purchases, sales or established pledges of shares in commercial companies by the issuer or its subsidiary.
- 1.8. The Group is monitoring the development of the military conflict in Ukraine, as well as the tension in the Middle East region, and assessing their impact on the activity, financial condition and future prospects. The Group has commercial relations with counterparties in Ukraine, Russia and Belarus, and the Management continuously monitors the applicable sanction regimes and assesses the risks associated with them. Management has conducted an analysis and determined that no significant issues have arisen in recent years regarding the collection of receivables from transactions typical of the business, and therefore considers that, as of the date of this report, there is no indication of a direct negative impact on transactions and operations with these counterparties, nor on their financial stability. As of the reporting date, no material direct effects on the Group's assets have been identified; the potential impact is primarily indirect and manifests as increased volatility in energy and transportation prices, disruptions in supply chains, and pressure on costs and margins. In preparing the financial statements, management has taken these factors into account when determining key estimates and assumptions, including regarding the collectability of receivables and future cash flows; as of the reporting date, no need for significant impairments or other adjustments has been identified. The geopolitical environment continues to be viewed as a source of uncertainty, but no events have occurred after the balance sheet date that would require that would require an adjustment.

The Management believes that the Group has sufficient resources to continue as a going concern, and continues to actively monitor developments and manage the associated risks.

In the first quarter of 2026, the company reported sales growth in Russia and Ukraine compared to the same period last year.

"Sopharma" AD informs all interested parties that the consolidated financial statements of the Company for the first quarter of 2026 have not been verified by a registered auditor.

**Information under Art. 12, para. 1, item 2 of REGULATION No. 2 of 09.11.2021 on initial and subsequent disclosure of information during the process of public offering of securities and admission of securities to trading on a regulated market.**

Electronic reference to the place on the website of the public company, where the internal information under Art. 7 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (Market Abuse Regulation) and Directive 2003/6/EC of the European Parliament and of the Council and Directives 2003 /124/EC, 2003/125/EC and 2004/72/EC of the Commission (OB, L 173/1 of 12 June 2014) (Regulation (EU) No 596/2014) regarding the circumstances that occurred in the first quarter of 2026, or an electronic reference to the issuer's chosen news agency or other media through which the company makes public the inside information:

During the period 01.01.2026 - 31.03.2026, "Sopharma" AD discloses information to the Financial Supervision Commission Authority, the Bulgarian Stock Exchange, the Warsaw Stock Exchange and the public, through the information platform x3news (<http://www.x3news.com>), through the company's corporate website in the "Investors" section ([https://www."Sopharma" group.com/bg/investitori/](https://www.)), on the information site investor.bg (<https://www.investor.bg/bulletin>) and on Biznes PAP ([Biznes PAP](#)).